RT Journal Article
SR Electronic
T1 Trends in demographic and clinical characteristics of patients enrolled in HIV care and subsequent Antiretroviral Therapy initiation in the Central Africa International epidemiology Database to Evaluate AIDS (CA-IeDEA) Adult Cohort 2004-2018
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.17.20156141
DO 10.1101/2020.07.17.20156141
A1 Adedimeji, Adebola A.
A1 Hoover, Donald R.
A1 Shi, Qiuhu
A1 Kim, Hae-Young
A1 Brazier, Ellen
A1 Ross, Jonathan
A1 Murenzi, Gad
A1 Twizere, Christella
A1 Lelo, Patricia
A1 Nsonde, Dominique
A1 Ajeh, Rogers
A1 Dzudie, Anastase
A1 Nash, Denis
A1 Yotebieng, Marcel
A1 Anastos, Kathryn M.
A1 for the Central Africa IeDEA Consortium
YR 2020
UL http://medrxiv.org/content/early/2020/07/17/2020.07.17.20156141.abstract
AB Background The Central Africa International epidemiology Database to Evaluate AIDS (CA-IeDEA) is a prospective study investigating impact, progression and long-term outcomes of HIV/AIDS among people living with HIV (PLWH) in Burundi, Cameroon, Democratic Republic of Congo (DRC), Republic of Congo (ROC) and Rwanda. We described trends in baseline demographic, clinical and immunological characteristics of patients aged >15 years entering into HIV care in the participating CA-IeDEA site and subsequent ART initiation.Materials and Methods Information on socio-demographic characteristics, height, weight, body mass index (BMI), CD4 cell count, WHO staging and ART status at entry into care from 2004 to 2018 were extracted from clinic records of patients aged >15 years enrolling in HIV care at participating clinics in Burundi, Cameroon, DRC, ROC and Rwanda. We assessed trends in patient characteristics at enrollment in HIV care and ART initiation at the participating site and calculated proportions, means and medians (interquartile ranges) for the main variables of interest.Results Among 69,176 participants in the CA-IeDEA cohort, 39% % were from Rwanda,, 24% from ROC, 18% from Cameroon, 14% from Burundi and 5% from DRC. More women (66%) than men were enrolled in care and subsequently initiated ART. Women were also younger (32 years) than men (38 years) (p= <0.001) when they enrolled in care or subsequently initiated ART at the participating site. Trends over time show increases in median CD4 cell count of 190 cells/uL in 2004 to 334 cells/uL in 2018 at enrollment. Among those with complete data on CD4 counts (60%), women had higher median CD4 cell count at care entry in the CA-IeDEA site (299 cells/uL) versus men (249 cells/uL; p= < 0.001).Trends in proportion of patients using ART show an increase from 16% in 2004 to 75% in 2018 among those initiating ART for the first time after entry into care in the participating site. As expected, median CD4 generally increased after ART initiation (p= <0.001).Conclusion Trends from 2004-2018 in the characteristics of patients participating in the CA-IeDEA cohort highlight improvements over time at entry into care and subsequent ART in all participating sites.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch reported in this publication was supported by the National Institutes of Health National Institute of Allergy and Infectious Diseases the Eunice Kennedy Shriver National Institute of Child Health & Human Development the National Cancer Institute the National Institute on Drug Abuse the National Heart, Lung, and Blood Institute the National Institute on Alcohol Abuse and Alcoholism the National Institute of Diabetes and Digestive and Kidney Diseases the Fogarty International Center the National Library of Medicine and the Office of the Director under Award Number U01AI096299- Central Africa-IeDEA. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the study was granted by the Albert Einstein College of Medicine Institutional Review Board Rwanda National Health Research Committee and the National Ethics Committee Comite National d Ethique Burundi Comite National D Ethique la Recherche en la Sante Humaine CNERSH, Cameroon, Ministere de l Enseignement Superieur et Universitaire University de Kinshasa Ecole de Sante Publique Democratic Republic of Congo and Comite d Ethique De La Recherche En Sciences De La Sante Republic of Congo.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData for the Central Africa International Epidemiology to Evaluate AIDS (CA-IeDEA) is available upon request.